Archive · 15 Aug 2025
Immunotherapy Drug 2141-V11 Shows Promise Against Aggressive Cancers
Scientists have developed an improved immunotherapy drug called 2141-V11 to fight aggressive cancers.
This drug is a type of antibody that helps the immune system attack cancer cells.
In early trials, it was injected into tumors and shrunk them in some patients.
Remarkably, it also caused tumors in other parts of the body to get smaller or disappear.
This new drug, unlike previous ones of its kind, didn't cause severe side effects, offering a safer way to combat cancer.
Two patients saw their cancer vanish entirely, showing a lot of potential for the future of cancer treatment.
Enhanced immunotherapy drug, 2141-V11, shows promise in Phase 1 trials.
The drug is a modified CD40 agonist antibody designed to boost efficacy and reduce side effects.
Six out of 12 patients experienced tumor shrinkage, with two achieving complete remission.
The drug's systemic effect led to tumor reduction in areas away from the injection site.
No serious side effects were reported in patients with melanoma, renal cell carcinoma, and breast cancer.
- Who
- Researchers led by Rockefeller University developed the drug, 2141-V11.
- What
- An enhanced immunotherapy drug showed promise against aggressive cancers in Phase 1 trials.
- When
- The Phase 1 clinical trial results were recently published.
- Where
- The research was conducted in the US.
- Why
- To improve the efficacy and limit the side effects of CD40 agonist antibodies.
- Drug Name
- 2141-V11
- Drug Type
- Enhanced CD40 agonist antibody
- Trial Phase
- Phase 1
- Patients with tumor shrinkage
- 6 out of 12
- Patients with complete remission
- 2
- Targeted Cancers
- Melanoma, renal cell carcinoma, breast cancer
- Administration Method
- Directly injected into tumors